Semnur Pharmaceuticals, Inc.
SMNR
$8.00
$0.000.00%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 906.28% | 14,120.75% | -37.95% | -16.87% | 43.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 693.56% | 11,656.09% | -10.00% | -55.84% | -16.42% |
| Operating Income | -693.56% | -11,656.09% | 10.00% | 55.84% | 16.42% |
| Income Before Tax | -693.56% | -11,656.09% | 10.00% | 55.84% | 16.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -693.56% | -11,656.09% | 10.00% | 55.84% | 16.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -693.56% | -11,656.09% | 10.00% | 55.84% | 16.42% |
| EBIT | -693.56% | -11,656.09% | 10.00% | 55.84% | 16.42% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -625.64% | -11,540.00% | 10.14% | 55.32% | 32.76% |
| Normalized Basic EPS | -637.50% | -11,434.15% | 9.30% | 55.93% | 33.33% |
| EPS Diluted | -625.64% | -11,540.00% | 10.14% | 55.32% | 32.76% |
| Normalized Diluted EPS | -637.50% | -11,434.15% | 9.30% | 55.93% | 33.33% |
| Average Basic Shares Outstanding | 8.72% | 0.84% | 0.00% | 0.00% | 25.00% |
| Average Diluted Shares Outstanding | 8.72% | 0.84% | 0.00% | 0.00% | 25.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |